Company / Operating Cash Flow
BioRestorative Therapies, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$10.8M
FY2025
5-year range
-$10.8M / -$3.3M
FY2021-FY2025
Trend
-67.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$11M in FY2025 to -$3M in FY2016.
Based on SEC 10-K filings.
-$11M in FY2025.
Declined from -$6M to -$11M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 67.8% year-over-year.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$10.8M | -67.8% |
| FY2024 | -$6.4M | +0.0% |
| FY2023 | -$6.4M | -8.7% |
| FY2022 | -$5.9M | -77.6% |
| FY2021 | -$3.3M | +51.9% |
| FY2020 | -$6.9M | -35.5% |
| FY2019 | -$5.1M | -32.5% |
| FY2018 | -$3.9M | +23.0% |
| FY2017 | -$5.0M | -60.2% |
| FY2016 | -$3.1M | +3.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026